LT3546458T - ((piridin-2-il)-amino)pirido[3,4-d]pirimidino ir ((piridazin-3-il)-amino)pirido[3,4-d]pirimidino dariniai, kaip cdk4/6 inhibitoriai, skirti gydymui, pvz. reumatoidinio artrito, arteriosklerozės, plaučių fibrozės, smegenų infarkto arba vėžio - Google Patents

((piridin-2-il)-amino)pirido[3,4-d]pirimidino ir ((piridazin-3-il)-amino)pirido[3,4-d]pirimidino dariniai, kaip cdk4/6 inhibitoriai, skirti gydymui, pvz. reumatoidinio artrito, arteriosklerozės, plaučių fibrozės, smegenų infarkto arba vėžio

Info

Publication number
LT3546458T
LT3546458T LTEP17874165.8T LT17874165T LT3546458T LT 3546458 T LT3546458 T LT 3546458T LT 17874165 T LT17874165 T LT 17874165T LT 3546458 T LT3546458 T LT 3546458T
Authority
LT
Lithuania
Prior art keywords
pyrido
amino
pyrimidine
cdk4
pyridazin
Prior art date
Application number
LTEP17874165.8T
Other languages
English (en)
Inventor
Tsuyoshi Mizuno
Tomohiro Shimada
Gen Unoki
Akinobu MARUYAMA
Kosuke Sasaki
Takuya YOKOSAKA
Hiroshi Takahashi
Kyohei HORIE
Yuri Sakai
Original Assignee
Teijin Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Limited filed Critical Teijin Pharma Limited
Publication of LT3546458T publication Critical patent/LT3546458T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
LTEP17874165.8T 2016-11-28 2017-11-27 ((piridin-2-il)-amino)pirido[3,4-d]pirimidino ir ((piridazin-3-il)-amino)pirido[3,4-d]pirimidino dariniai, kaip cdk4/6 inhibitoriai, skirti gydymui, pvz. reumatoidinio artrito, arteriosklerozės, plaučių fibrozės, smegenų infarkto arba vėžio LT3546458T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016229969 2016-11-28
PCT/JP2017/042443 WO2018097297A1 (ja) 2016-11-28 2017-11-27 ピリド[3,4-d]ピリミジン誘導体及びその薬学的に許容される塩

Publications (1)

Publication Number Publication Date
LT3546458T true LT3546458T (lt) 2021-05-10

Family

ID=62194988

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17874165.8T LT3546458T (lt) 2016-11-28 2017-11-27 ((piridin-2-il)-amino)pirido[3,4-d]pirimidino ir ((piridazin-3-il)-amino)pirido[3,4-d]pirimidino dariniai, kaip cdk4/6 inhibitoriai, skirti gydymui, pvz. reumatoidinio artrito, arteriosklerozės, plaučių fibrozės, smegenų infarkto arba vėžio

Country Status (27)

Country Link
US (1) US11084814B2 (lt)
EP (1) EP3546458B1 (lt)
JP (1) JP6785876B2 (lt)
KR (1) KR102290815B1 (lt)
CN (1) CN110036012B (lt)
AR (1) AR110238A1 (lt)
AU (1) AU2017364807B2 (lt)
CA (1) CA3043561C (lt)
CL (1) CL2019001419A1 (lt)
CO (1) CO2019005514A2 (lt)
CY (1) CY1123850T1 (lt)
DK (1) DK3546458T3 (lt)
ES (1) ES2852123T3 (lt)
HR (1) HRP20210285T1 (lt)
HU (1) HUE053220T2 (lt)
IL (1) IL266312B (lt)
LT (1) LT3546458T (lt)
MX (1) MX389537B (lt)
MY (1) MY196497A (lt)
PH (1) PH12019501171A1 (lt)
PL (1) PL3546458T3 (lt)
PT (1) PT3546458T (lt)
SA (1) SA519401827B1 (lt)
SI (1) SI3546458T1 (lt)
TW (1) TWI799399B (lt)
WO (1) WO2018097297A1 (lt)
ZA (1) ZA201902893B (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022037592A1 (zh) * 2020-08-17 2022-02-24 南京明德新药研发有限公司 嘧啶并环类化合物
CN113636973B (zh) * 2021-09-07 2023-04-07 山东铂源药业股份有限公司 一种4-(6-氨基吡啶-3-基)哌嗪-1-羧酸叔丁酯的工业化制备方法
CN116354957A (zh) * 2021-12-16 2023-06-30 药捷安康(南京)科技股份有限公司 Cdk9抑制剂及其用途
WO2023155841A1 (zh) * 2022-02-16 2023-08-24 南京明德新药研发有限公司 嘧啶并环类化合物的盐型、晶型
CN120051470A (zh) * 2022-07-18 2025-05-27 依安彼克医疗有限公司 氮杂喹唑啉化合物及使用方法
US20250235456A1 (en) * 2024-01-17 2025-07-24 Iambic Therapeutics, Inc. Methods of use for aza-quinazoline compounds
TW202545531A (zh) * 2024-01-17 2025-12-01 美商依安彼克醫療有限公司 氮—喹唑啉化合物之使用方法
CN120424049B (zh) * 2025-06-09 2026-01-23 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 一种含杂环嘧啶类化合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JP2012504646A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ4/6阻害剤を用いた化学療法化合物に対する造血系の防護
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
CA2809836C (en) 2010-09-01 2019-01-15 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
GB201216017D0 (en) * 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
AU2014308616B2 (en) * 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR101901123B1 (ko) * 2013-09-30 2018-09-27 써튼티드 코포레이션 방오성 및 voc 제거 코팅물 및 이의 용도
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR20170032244A (ko) * 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
DK3305785T3 (da) * 2015-05-29 2021-10-11 Teijin Pharma Ltd Pyrido[3,4-d]pyrimidinderivat og farmaceutisk acceptabelt salt deraf

Also Published As

Publication number Publication date
CN110036012A (zh) 2019-07-19
WO2018097297A1 (ja) 2018-05-31
CA3043561A1 (en) 2018-05-31
US11084814B2 (en) 2021-08-10
PH12019501171A1 (en) 2021-02-08
JP6785876B2 (ja) 2020-11-18
CY1123850T1 (el) 2022-05-27
SA519401827B1 (ar) 2022-07-28
IL266312A (en) 2019-06-30
CA3043561C (en) 2025-03-11
CL2019001419A1 (es) 2019-08-30
JPWO2018097297A1 (ja) 2019-06-24
EP3546458B1 (en) 2021-01-06
RU2019116137A (ru) 2020-11-27
IL266312B (en) 2021-08-31
MY196497A (en) 2023-04-17
BR112019010674A2 (pt) 2019-10-01
CO2019005514A2 (es) 2019-07-31
KR20190066631A (ko) 2019-06-13
MX389537B (es) 2025-03-20
AR110238A1 (es) 2019-03-13
TW201831476A (zh) 2018-09-01
RU2019116137A3 (lt) 2021-08-13
NZ752823A (en) 2025-08-29
PL3546458T3 (pl) 2021-06-14
CN110036012B (zh) 2022-05-10
EP3546458A4 (en) 2019-10-09
MX2019005803A (es) 2019-09-10
AU2017364807B2 (en) 2021-05-13
DK3546458T3 (da) 2021-02-22
ZA201902893B (en) 2020-01-29
HRP20210285T1 (hr) 2021-04-02
HUE053220T2 (hu) 2021-06-28
PT3546458T (pt) 2021-02-25
US20190367510A1 (en) 2019-12-05
KR102290815B1 (ko) 2021-08-18
AU2017364807A1 (en) 2019-05-16
TWI799399B (zh) 2023-04-21
EP3546458A1 (en) 2019-10-02
SI3546458T1 (sl) 2021-03-31
ES2852123T3 (es) 2021-09-13

Similar Documents

Publication Publication Date Title
LT3546458T (lt) ((piridin-2-il)-amino)pirido[3,4-d]pirimidino ir ((piridazin-3-il)-amino)pirido[3,4-d]pirimidino dariniai, kaip cdk4/6 inhibitoriai, skirti gydymui, pvz. reumatoidinio artrito, arteriosklerozės, plaučių fibrozės, smegenų infarkto arba vėžio
IL266170A (en) A process for the preparation of pyrazolo[1,5-a]pyrimidines and their salts
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
ZA201904548B (en) Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
IL265918A (en) Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors
EP3268000A4 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
PL3345907T3 (pl) Związki pirazolo[3,4-d]pirymidynowe lub ich sole
SI3305785T1 (sl) Derivat pirido(3,4-D)pirimidina in njegova farmacevtsko sprejemljiva sol
IL268923A (en) History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity
ZA201902828B (en) Crystal of pyrido[3, 4-d]pyrimidine derivative or solvate thereof
HUE052997T2 (hu) JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok
HUE050298T2 (hu) Pirazolo[3,4-D]pirimidin vegyületek vagy annak sói
HK40010045A (en) Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer